Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's saves $476 million from Boehringer buy:

This article was originally published in Clinica

Executive Summary

Roche says it has achieved 70% of potential synergies from its acquisition in mid-1997 of Boehringer Mannheim, with savings of around SwFr700 million ($476 million). The Swiss company also reported its net income for the full year - SwFr4.4 billion, a 3% increase on the previous year. Roche, which published sales figures in January (see Clinica No 842, p 8), anticipates another good result for 1999. The company also announced that chairman Fritz Gerber will be retiring. Franz Humer has been appointed CEO and as delegate to the board, and the company plans to elect Dr Humer as chairman on Mr Gerber's retirement.

You may also be interested in...



Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.

Topics

UsernamePublicRestriction

Register

MT077785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel